Phathom Pharmaceuticals, Inc. (PHAT)
PHATNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$5.33
+0.0800 (+1.52%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $433.28m
- P/E
- –
- EPS, last 4 quarters
- $-0.5200
- Dividend yield
- –
- Day range
- –
- 52-week range
- $5.02 to $18.31
- Average volume
- 1.49m
- Previous close
- $5.25
Analysts
6 coveringBuy5 buy, 1 hold, 0 sell
Targets a year out average $16.90, +217.1% from here
Earnings
next estimate $0.0500Next report
Dec 2025
+20.0%
Mar 2026
+7.4%
Jun 2026
+46.7%
Sep 2026
-200.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $57.58m | $58.30m | $74.27m | $84.72m |
| Gross profit | $49.94m | $46.30m | $59.18m | $66.36m |
| Operating income | -$5.93m | -$15.48m | -$3.96m | -$86.0k |
| Net income | -$21.15m | -$30.37m | -$17.58m | -$13.90m |
Last four quarters: revenue $274.88m, margin -30.2%, free cash flow -$21.04m
News
8 latest- Implied Volatility Surging for Phathom Pharmaceuticals Stock OptionsZacks · 4 days ago
- What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings CallMarketBeat · Oct 29, 2026
- Phathom Pharmaceuticals Q3 Revenue Jumps 71%; Reaffirms FY26 Outlook RTTNews · Oct 29, 2026
- Phathom (PHAT) Q3 2026 Earnings Call TranscriptThe Motley Fool · Oct 29, 2026
- Phathom Pharmaceuticals Reports Q3 2026 Net Revenues of $84.7 millionFintel · Oct 29, 2026
- Phathom Pharmaceuticals, Inc. (PHAT) Lags Q3 Earnings and Revenue EstimatesZacks · Oct 29, 2026
- FDA Establishes Public Docket FDA-2026-N-13038 Following Challenge to VOQUEZNA ExclusivityFintel · Oct 26, 2026
- Phathom Defends VOQUEZNA Exclusivity As FDA Seeks Comments On Generic Drug Dispute; Stock Down RTTNews · Oct 26, 2026
The company
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- phathompharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.